The AKR7A2P1 Gene: Potential Drug Target and Biomarker (G246182)

Target Name: AKR7A2P1

NCBI ID: G246182

AKR7A2P1

Other Name(s): AKR7A2 pseudogene 1 | AFARP1

The AKR7A2P1 Gene: Potential Drug Target and Biomarker

The AKR7A2 pseudogene 1 (AKR7A2P1) is a gene that has been identified in various studies as having potential drug targets or as a biomarker for various diseases. The AKR7A2 gene is located on chromosome 16 and encodes a protein known as Amino Kallikrein-Related Receptor 2 (AKSR2). The primary function of the AKSR2 protein is to regulate the production of kallikrein, a serine protease that can cause a number of diseases, including angiogenesis, cancer, and neurodegeneration.

Disease-Causation Interpretation

The AKR7A2P1 gene has been associated with a number of diseases due to its involvement in the regulation of kallikrein production. One of the primary diseases associated with the AKR7A2P1 gene is angiogenesis, which is the process by which new blood vessels are formed in the body. In cancer, the AKR7A2P1 gene has been shown to be involved in the regulation of angiogenesis, and therefore, it has potential as a drug target for cancer treatment.

Another disease that is associated with the AKR7A2P1 gene is neurodegeneration, which is the progressive loss of brain cells that can result in a variety of disorders, including Alzheimer's and Parkinson's diseases. Studies have shown that the AKR7A2P1 gene is involved in the regulation of neurogenesis, which is the process by which new neurons are produced in the brain.

Drug Targets

The AKR7A2P1 gene has been identified as a potential drug target for a variety of diseases due to its involvement in the regulation of kallikrein production. One of the primary drug targets for the AKR7A2P1 gene is the inhibition of serine proteases, which can cause a number of diseases, including cancer, angiogenesis, and neurodegeneration.

There are a number of different drugs that have been developed to inhibit serine proteases, and these drugs have been shown to be effective in treating a variety of diseases. For example, drugs such as inhibitors of proteasome-mediated degradation, or inhibitors of intracellular serine proteases, have been shown to be effective in treating cancer, angiogenesis, and neurodegeneration.

Biomarkers

The AKR7A2P1 gene has also been identified as a potential biomarker for a variety of diseases due to its involvement in the regulation of kallikrein production. The production of kallikrein is a highly sensitive process that can be used as a biomarker for a variety of diseases.

For example, the production of kallikrein has been shown to be involved in the regulation of angiogenesis, and therefore, it can be used as a biomarker for the diagnosis and treatment of angiogenic diseases, such as cancer and neurodegeneration. Additionally, the production of kallikrein has been shown to be involved in the regulation of neurogenesis, and therefore, it can be used as a biomarker for the diagnosis and treatment of neurodegenerative diseases.

Conclusion

The AKR7A2P1 gene has been identified as a potential drug target and biomarker for a variety of diseases due to its involvement in the regulation of kallikrin production. The primary functions of the AKSR2 protein are to regulate the production of kallikrin, a serine protease that can cause a number of diseases, including angiogenesis, cancer, and neurodegeneration. The AKR7A2P1 gene has also been shown to be involved in the regulation of neurogenesis, which is the process by which new neurons are produced in the brain.

Further research is needed to fully understand the role of the AKR7A2P1 gene in the regulation of kallikrin production and its potential as a drug target and biomarker for a variety of diseases.

Protein Name: AKR7A2 Pseudogene 1

The "AKR7A2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKR7A2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets